Heart attack care lags as hospitals recover from the pandemic

A door-to-balloon (D2B) time of 90-minutes or less is associated with improved outcomes for heart attack patients.

C3-Binding Polypeptide by Boehringer Ingelheim International for Unspecified Ophthalmological Disorders: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

January 6, 2025

CGSI Reiterates “Buy” Rating on Modern Dental (03600HK), Ups Target Price to HK$5.88 – Biotech Investments

EQS Newswire / 10/04/2024 / 11:50 UTC+8 CGSI Reiterates “Buy” Rating on Modern Dental (03600HK), Ups Target Price to HK$5.88 In a recent

April 11, 2024

Boehringer’s obesity drug shows efficacy for liver disease – Pharmaceutical Technology

Share this article Boehringer is also investigating survodutide’s efficacy in obesity in five clinical trials. Credit: Michael Vi via Shutterstock. Boehringer Ingelheim’s glucagon/GLP-1 receptor dual

February 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.